. 2012 Jun 3;2012:626094. doi: 10.1155/2012/626094

Table 1.

Targets, drugs, and clinical trials. Drugs and their specific targets in sarcoma treatment and clinical trials with their results: positive (+), negative (−), or not published (x).

	Target	Drug	Clinical trial
Vascular endothelial growth factor	Tyrosine kinase inhibitors	Sunitinib	+	Phase II trial: non:GIST sarcoma [18].
			`+`	Phase II trial: leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. [19].
			−	Phase II study: treatment of recurrent/persistent uterine leiomyosarcoma [20].
		Sorafenib	`+`	Phase II trial: patients with metastatic or recurrent sarcomas [28].
			`+`	Phase II trial: efficacy of sorafenib in STS [31].
			`+`	Phase II trial: relapsed and unresectable high-grade osteosarcoma [29].
			`+`	Phase II trial: advanced vascular sarcoma, high grade liposarcoma and leiomyosarcoma [30].
		Pazopanib	`+`	Phase II trial: patients with relapsed or refractory advanced STS [32].
			`+`	Phase III trial: placebo-controlled randomized trial in advanced STS [33].
		Dasatinib	x	No results published.
	Anti-VEGF antibodies	Bevacizumab	`+`	Phase II trial: doxorubicin and bevacizumab in patients with metastatic STS [43].
			`+`	Phase IB trial: efficacy of bevacizumab in combination with other drugs [44].

Insulin-like growth factor	Tyrosine kinase inhibitors	Clinical development	`x`	No results published.
	Anti-IGFR1 antibodies	AMG 479	`+`	Phase I trial: response of sarcoma patients to a fully monoclonal antibody to IGFR-1 [68].
		Figitumumab	−	Phase I trial: different sarcoma patients [70].
		IMC-A12 (cixutumumab)	`+`	Phase II trial: patients with advanced or metastatic STS and Ewing Sarcoma [91].

Mammalian target of rapamycin	mTORC1 tyrosine kinase inhibitors	Sirolimus	−	Phase II trial: combination with cyclophosphamide in sarcomas [91].
		Temsirolimus	`+`	Phase II trial: temsirolimus in pediatric patients with neuroblastoma, high-grade glioma, and rhabdomyosarcoma [95].
			`−`	Phase II trial: treatment in STS patients [94]
			`+`	Phase II trial: everolimus in STS or bone sarcoma [97]
		Everolimus	`+`	Phase II trial: treatment in patients with advanced bone and soft tissue sarcomas [99].
		Ridaforolimus	`+`	Phase III trial: placebo-controlled randomized sarcoma patient [99].

Hepatocyte growth factor receptor	MET inhibitors	ARQ197	`+`	Phase II trial: patients with microph thalmia transcription-family-(MiT-) associated tumors [107].
Virus	Tumor cell	Oncolytic poxvirus	`+`	Phase I trial: oncolytic poxvirus in different cancer patients [109].
Insulin-like growth factor/ mammalian target of rapamycin	Tyrosine kinase inhibitors	Figitumumab/ everolimus	`+`	Phase I trial: advanced sarcoma patients and other solid tumors [114].
Insulin-like growth factor/ mammalian target of rapamycin	Tyrosine kinase inhibitors	Cixutumumab/ temsirolimus	`+`	Phase I trial: patients with advanced cancer including sarcomas [115].

Other targets	ALK inhibitors	Crizotinib	`+`	Phase I trial: inflammatory myofibroblastic tumor with ALK overexpression [116].
	HDAC inhibitors		`+`	Ongoing clinical trials.
	PI3K/mTOR	NVP-BEZ235	`+`	Ongoing clinical trials.